tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2025-103-4-24-31tiblj-1902Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESПрофилактика туберкулеза фторхинолонами, в том числе моксифлоксацином, у детей из контакта с больными туберкулезом с множественной лекарственной устойчивостьюPreventive Treatment of Tuberculosis with Fluoroquinolones Including Moxifloxacin in Children Exposed to Multidrug-Resistant TuberculosisГурьеваТ. И.GuryevaT. I.

Гурьева Татьяна Ивановна, заведующая отделом качества и организационно-методической работы, аспирант кафедры фтизиопульмонологии

163002, г. Архангельск, Новгородский пр-кт, д. 28 Тел.: +7 (8182) 66-05-62163069, г. Архангельск, Троицкий пр-кт, д. 51 Тел.: + 7 (8182) 66-05-64

 

Tatiana I. Guryeva, Head of Department for Quality Control and Statistic Reporting, Post Graduate Student of Phthisiopulmonology Department

28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62

51 Troitsky Ave., Arkhangelsk, 163069 Phone: + 7 (8182) 66-05-64

tanya-gyrieva@yandex.ruНикишоваЕ. И.NikishovaE. I.

Никишова Елена Ильинична, д. м. н., профессор кафедры фтизиопульмонологии

163069, г. Архангельск, Троицкий пр-кт, д. 51 Тел.: + 7 (8182) 66-05-64

Elena I. Nikishova, Doctor of Medical Sciences, Professor of Phthisiopulmonology Department

51 Troitsky Ave., Arkhangelsk, 163069 Phone: + 7 (8182) 66-05-64

e.i.nikishova@mail.ruЗолотаяО. А.ZolotayaO. A.

Золотая Ольга Александровна, врач-фтизиатр

163002, г. Архангельск, Новгородский пр-кт, д. 28 Тел.: +7 (8182) 66-05-62

Olga A. Zolotaya, Phthisiologist

28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62

ol.zolotaya@yandex.ruСвешниковаО. М.SveshnikovaO. M.

Свешникова Оксана Михайловна, заместитель главного врача по медицинской части

163002, г. Архангельск, Новгородский пр-кт, д. 28 Тел.: +7 (8182) 66-05-62

Oksana M. Sveshnikova, Deputy Head Doctor for Medical Activities

28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62

tub29zam@mail.ruПерхинД. В.PerkhinD. V.

Перхин Дмитрий Валентинович, главный врач

163002, г. Архангельск, Новгородский пр-кт, д. 28 Тел.: +7 (8182) 66-05-62

Dmitriy V. Perkhin, Head Physician

28 Novgorodsky Ave., Arkhangelsk, 163002 Phone: +7 (8182) 66-05-62

dperchin@gmail.comМарьяндышевА. О.MaryandyshevA. O.

Марьяндышев Андрей Олегович, член-корренспондент РАН, д. м. н., профессор, заведующий кафедрой фтизиопульмонологии, ведущий научный сотрудник департамента научных исследований

163002, г. Архангельск, Новгородский пр-кт, д. 28 Тел.: +7 (8182) 66-05-62163069, г. Архангельск, Троицкий пр-кт, д. 51 Тел.: + 7 (8182) 66-05-64

Andrey O. Maryandyshev, Correspondent Member of RAS, Doctor of Medical Sciences, Professor, Head of Phthisiopulmonology Department, Leading Researcher of Research Department

51 Troitsky Ave., Arkhangelsk, 163069 Phone: + 7 (8182) 66-05-64

 

maryandyshev@mail.ruГБУЗ АО «Архангельский клинический противотуберкулезный диспансер»; ФГБОУ ВО «Северный государственный медицинский университет» МЗ РФРоссияArkhangelsk Clinical TB Dispensary; Northern State Medical UniversityRussian FederationФГБОУ ВО «Северный государственный медицинский университет» МЗ РФРоссияNorthern State Medical UniversityRussian FederationГБУЗ АО «Архангельский клинический противотуберкулезный диспансер»РоссияArkhangelsk Clinical TB DispensaryRussian FederationФГБОУ ВО «Северный государственный медицинский университет» МЗ РФ; ФГАОУ ВО «Северный (Арктический) федеральный университет имени М.В. Ломоносова»РоссияNorthern State Medical University; Northern (Arctic) Federal UniversityRussian Federation20251209202510342431Copyright © Гурьева Т.И., Никишова Е.И., Золотая О.А., Свешникова О.М., Перхин Д.В., Марьяндышев А.О., 20252025Гурьева Т.И., Никишова Е.И., Золотая О.А., Свешникова О.М., Перхин Д.В., Марьяндышев А.О.Guryeva T.I., Nikishova E.I., Zolotaya O.A., Sveshnikova O.M., Perkhin D.V., Maryandyshev A.O.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1902

Цель исследования: установить эффективность и безопасность профилактики туберкулеза фторхинолонами у детей из тесного семейного контакта с больными туберкулезом с множественной лекарственной устойчивостью (МЛУ-ТБ).Материалы и методы. В Архангельской области с 01.01.2011 по 31.12.2021 гг. проведено когортное проспективное исследование детей из контактов с МЛУ-ТБ, получивших или не получивших профилактическое лечение.Результаты. В исследование были включены 286 детей в возрасте от 0 до 18 лет, находившихся в контакте с 939 взрослыми больными МЛУ-ТБ. Из 286 детей 37 имели контакт в семье более чем с одним взрослым с МЛУ-ТБ, 3 детей имели сразу 5 контактов, 2 ребенка – 4 контакта, 8 – по 3 контакта и 24 – 1 по контакту. Из 225 детей, получивших профилактическое лечение фторхинолонами, не было случаев заболевания туберкулезом на 01.03.2024 г. Среди 61 ребенка, не прошедшего профилактическое лечение, был 1 (1,64%) случай заболевания туберкулезом, что соответствует заболеваемости 1639,3 на 100 тыс. контингента. Неблагоприятные реакции на прием фторхинолона были зарегистрированы у 48/225 (21,33%) детей, из них у 8/225 (3,6%) – являлись серьезными. Все неблагоприятные реакции были устранены.

The objective: to establish effectiveness and safety of preventive treatment of tuberculosis with fluoroquinolones in children exposed to multidrug-resistant tuberculosis (MDR TB) in their families.Subjects and Methods. A cohort prospective study was conducted in Arkhangelsk Region from January 01, 2011 to December 31, 2021. Children exposed to MDR TB who received or did not receive preventive treatment were enrolled in the study.Results. 286 children aged 0 to 18 years exposed to 939 adult MDR TB patients were included in the study. Of the 286 children, 37 were exposed to more than one adult with MDR TB, 3 children were exposed to 5 cases, 2 children were exposed to 4 cases, 8 children were exposed to 3 cases, and 24 children were exposed to 1 case. Of the 225 children who received preventive treatment with fluoroquinolones, there were no cases of tuberculosis as of March 1, 2024. Among 61 children who received no preventive treatment, there was 1 (1.64%) case of tuberculosis, which corresponded to the rate of 1639.3 per 100,000 contingent. Adverse reactions to fluoroquinolone were reported in 48/225 (21.33%) children, of which 8/225 (3.6%) were serious ones. All adverse reactions resolved.

МЛУ-ТБфторхинолоныпрофилактическое лечениедетиMDR TBfluoroquinolonespreventive treatmentchildrenReferencesКлинические рекомендации «Туберкулез у взрослых». Общероссийская общественная организация «Российское общество фтизиатров», Национальная ассоциация некоммерческих организаций фтизиатров «Ассоциация фтизиатров», 2022.Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults]. All-Russia Non-Commercial Organization of the Russian Society of Phthisiologists, National Association of Non-profit Organizations of Phthisiologists Association of Phthisiologists, 2022.Клинические рекомендации «Туберкулез у детей». Общероссийская общественная организация «Российское общество фтизиатров», Национальная ассоциация некоммерческих организаций фтизиатров «Ассоциация фтизиатров», 2022.Klinicheskie rekomendatsii Tuberkulez u detey. [Clinical guidelines on tuberculosis in children]. All-Russia Non-Commercial Organization of the Russian Society of Phthisiologists, National Association of Non-profit Organizations of Phthisiologists Association of Phthisiologists, 2022.Клинические рекомендации «Латентная туберкулезная инфекция у детей». Общероссийская общественная организация «Российское общество фтизиатров», Национальная ассоциация некоммерческих организаций фтизиатров «Ассоциация фтизиатров», 2024.Klinicheskie rekomendatsii. Latentnaya tuberkuleznaya infektsiya u detey. [Guidelines. Latent tuberculous infection in children]. All-Russia Non-Commercial Organization of the Russian Society of Phthisiologists, National Association of Non-profit Organizations of Phthisiologists Association of Phthisiologists, 2024.Постников С.С., Семыкин С. Ю., Нажимов В.П., Каменев А.И. Хондро- токсичны ли фторхинолоны у детей? (20 летний опыт применения) // Безопасность и риск фармакотерапии. – 2015. – № 2. – С. 40-47.Postnikov S.S., Semykin S.Yu., Nazhimov V.P., Kamenev A.I. Chondrotoxicity of fluoroquinolones in children: yes or no? Safety and Risk of Pharmacotherapy. 2015, no. 2, pp. 40-47. (In Russ.)Приказ Министерства здравоохранения РФ от 15 ноября 2012 г. № 932н «Об утверждении Порядка оказания медицинской помощи больным туберкулезом» (с изменениями и дополнениями) URL: https://base.garant.ru/70340750/?ysclid=meogeztaw930488044 [Дата обращения 20.11.2024]Edict no. 932n as of 15.11.12 by the Russian MoH On Approval of Procedure for Medical Care Provision to Tuberculosis Patients (with amendments and supplements). (In Russ.) Available: https://base.garant.ru/70340750/?ysclid=meogeztaw930488044 Accessed November 20, 2024Adler-Shohet F.C., Low J., Carson M., Girma H., Singh J. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis // Pediatr Infect Dis J. – 2014. – Vol. 33, № 6. – Р. 664-666. https://doi.org/10.1097/INF.0000000000000260Adler-Shohet F.C., Low J., Carson M., Girma H., Singh J. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. Pediatr. Infect. Dis. J., 2014, vol. 33, no. 6, pp. 664-666. https://doi.org/10.1097/INF.0000000000000260Bamrah S., Brostrom R., Dorina F., Setik L., Song R., Kawamura L.M., Heetderks A., Mase S. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012 // Int J Tuberc Lung Dis. – 2014. – Vol. 18, № 8. – Р. 912-918. https://doi.org/10.5588/ijtld.13.0028Bamrah S., Brostrom R., Dorina F., Setik L., Song R., Kawamura L.M., Heetderks A., Mase S. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 8, pp. 912-918. https://doi.org/10.5588/ijtld.13.0028Dodd P.J., Sismanidis C., Seddon J.A. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study // Lancet Infect Dis. – 2016. – Vol. 16, № 10. – Р. 1193-1201. https://doi.org/10.1016/S1473-3099(16)30132-3Dodd P.J., Sismanidis C., Seddon J.A. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis., 2016, vol. 16, no. 10, pp. 1193-1201. https://doi.org/10.1016/S1473-3099(16)30132-3Garcia-Prats A.J., Zimri K., Mramba Z., Schaaf H.S., Hesseling A.C. Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation // Int J Tuberc Lung Dis. – 2014. – Vol. 18, № 11. – Р. 1292-1298. https://doi.org/10.5588/ijtld.13.0872.Garcia-Prats A.J., Zimri K., Mramba Z., Schaaf H.S., Hesseling A.C. Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 11, pp. 1292-1298. https://doi.org/10.5588/ijtld.13.0872.Global consultation on best practices in the delivery of preventive therapy for household contacts of patients with drug-resistant tuberculosis. –Vol. 1, № 1. Proceedings of the Harvard Medical School Center for Global Health Delivery–Dubai, 2015.Global consultation on best practices in the delivery of preventive therapy for household contacts of patients with drug-resistant tuberculosis. vol. 1, no. 1. Proceedings of the Harvard Medical School Center for Global Health Delivery, Dubai, 2015.Global Tuberculosis Network, Migliori G.B., Tiberi S., Zumla A., Petersen E., Chakaya J. M., Wejse C., Muñoz Torrico M., Duarte R., Alffenaar J. W., Schaaf H.S., Marais B.J., Cirillo D.M., Alagna R., Rendon A., Pontali E., Piubello A., Figueroa J., et al. MDR/XDR-TB Management of Patients and Contacts: Challenges Facing the New Decade. The 2020 Clinical Update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 92, S15-S25. Advance online publication, 2020. https://doi.org/10.1016/j.ijid.2020.01.042Global Tuberculosis Network, Migliori G.B., Tiberi S., Zumla A., Petersen E., Chakaya J.M., Wejse C., Muñoz Torrico M., Duarte R., Alffenaar J.W., Schaaf H.S., Marais B.J., Cirillo D.M., Alagna R., Rendon A., Pontali E., Piubello A., Figueroa J. et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 Clinical Update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 92, S15-S25. Advance online publication, 2020. https://doi.org/10.1016/j.ijid.2020.01.042Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO, 2023.Global tuberculosis report, 2023. Geneva, World Health Organization, 2023. Licence: CC BY-NC-SA 3.0 IGO, 2023.Gureva T., Turkova A., Yablokova E., Smirnova P., Sveshnikova O., Zolotaya O., Nikishova E., Heldal E., Hinderaker S., Seddon J.A., Mariandyshev A. Fluoroquinolone preventive therapy for children exposed to MDR-TB // Int J Tuberc Lung Dis. – 2022. – Vol. 26, № 2. – Р. 171-173. https://doi.org/10.5588/ijtld.21.0443Gureva T., Turkova A., Yablokova E., Smirnova P., Sveshnikova O., Zolotaya O., Nikishova E., Heldal E., Hinderaker S., Seddon J.A., Mariandyshev A. Fluoroquinolone preventive therapy for children exposed to MDR-TB. Int. J. Tuberc. Lung Dis., 2022, vol. 26, no. 2, pp. 171-173. https://doi.org/10.5588/ijtld.21.0443How to care for people exposed to drug-resistant tuberculosis: a practical guide. Boston, USA: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis; First edition, 2018.How to care for people exposed to drug-resistant tuberculosis: a practical guide. Boston, USA. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. First edition, 2018.Jenkins H.E., Tolman A.W., Yuen C.M., Parr J.B., Keshavjee S., Pérez-Vélez C.M., Pagano M., Becerra M.C., Cohen T. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates // Lancet. – 2014. – Vol. 383, № 9928. – Р. 1572-1579. https://doi.org/10.1016/S0140-6736(14)60195-1Jenkins H.E., Tolman A.W., Yuen C.M., Parr J.B., Keshavjee S., Pérez-Vélez C.M., Pagano M., Becerra M.C., Cohen T. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014, vol. 383, no. 9928, pp. 1572-1579. https://doi.org/10.1016/S0140-6736(14)60195-1Jenkins H.E., Yuen C.M. The burden of multidrug-resistant tuberculosis in children // Int J Tuberc Lung Dis. – 2018. – Vol. 22. – № 5. – Р. 3-6. https://doi.org/10.5588/ijtld.17.0357Jenkins H.E., Yuen C.M. The burden of multidrug-resistant tuberculosis in children. Int. J. Tuberc. Lung Dis., 2018, vol. 22, no. 5, pp. 3-6. https://doi.org/10.5588/ijtld.17.0357Malik A.A., Becerra M.C., Lash T.L., Cranmer L.M., Omer S.B.., Fuad J., Siddiqui S., Amanullah F., et al. Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure // Clin Infect Dis. – 2021. – Vol. 72, № 10. – Р. 1709-1715. https://doi.org/10.1093/cid/ciaa327Malik A.A., Becerra M.C., Lash T.L., Cranmer L.M., Omer S.B.., Fuad J., Siddiqui S., Amanullah F. et al. Risk factors for adverse events in household contacts prescribed preventive treatment for drug-resistant tuberculosis exposure. Clin. Infect. Dis., 2021, vol. 72, no. 10, pp. 1709-1715. https://doi.org/10.1093/cid/ciaa327Malik A.A., Fuad J., Siddiqui S., Amanullah F., Jaswal M., Barry Z., Jabeen F., Fatima R., Yuen C.M., et al. Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen // Clin Infect Dis. – 2020. – Vol. 70, № 9. – Р. 1958-1965. https://doi.org/10.1093/cid/ciz502Malik A.A., Fuad J., Siddiqui S., Amanullah F., Jaswal M., Barry Z., Jabeen F., Fatima R., Yuen C.M. et al. Tuberculosis preventive therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen. Clin. Infect. Dis., 2020, vol. 70, no. 9, pp. 1958-1965. https://doi.org/10.1093/cid/ciz502Nahid P., Mase S.R., Migliori G.B., Sotgiu G., Bothamley G.H., Brozek J.L., Cattamanchi A., Cegielski J.P., et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline // Am J RespirCrit Care Med. – 2019. – Vol. 200, № 10. – Р. e93-e142. https://doi.org/10.1164/rccm.201909-1874STNahid P., Mase S.R., Migliori G.B., Sotgiu G., Bothamley G.H., Brozek J.L., Cattamanchi A., Cegielski J.P. et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am. J. Respir. Crit. Care Med., 2019, vol. 200, no. 10, pp. e93-e142. https://doi.org/10.1164/rccm.201909-1874STPatel K., Goldman J.L. Safety Concerns Surrounding Quinolone Use in Children // British Journal of Clinical Pharmacology. – 2016. – Vol. 56, № 9. – Р. 1060-1075. https://doi.org/10.1002/jcph.715Patel K., Goldman J.L. Safety concerns surrounding quinolone use in children. British Journal of Clinical Pharmacology, 2016, vol. 56, no. 9, pp. 1060-1075. https://doi.org/10.1002/jcph.715Radtke K.K., Hesseling A.C., Winckler J.L., Draper H.R., Solans B.P., Thee S., Wiesner L., van der Laan L.E., et al. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children // Clin Infect Dis. – 2022. – Vol. 74, № 8. – Р. 1372-1381. https://doi.org/10.1093/cid/ciab641Radtke K.K., Hesseling A.C., Winckler J.L., Draper H.R., Solans B.P., Thee S., Wiesner L., van der Laan L.E. et al. Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. Clin. Infect. Dis., 2022, vol. 74, no. 8, pp. 1372-1381. https://doi.org/10.1093/cid/ciab641Seddon J.A., Hesseling A.C., Finlayson H., Fielding K., Cox H., Hughes J., Godfrey-Faussett P., Schaaf H.S. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study // Clin Infect Dis. – 2013. – Vol. 57, № 12. – Р. 1676-1684. https://doi.org/10.1093/cid/cit655Seddon J.A., Hesseling A.C., Finlayson H., Fielding K., Cox H., Hughes J., Godfrey-Faussett P., Schaaf H.S. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin. Infect. Dis., 2013, vol. 57, no. 12, pp. 1676-1684. https://doi.org/10.1093/cid/cit655Shah N.S., Yuen C.M., Heo M., Tolman A.W., Becerra M.C. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis // Clin Infect Dis. – 2014. – Vol. 58, № 3. – Р. 381-391. https://doi.org/10.1093/cid/cit643Shah N.S., Yuen C.M., Heo M., Tolman A.W., Becerra M.C. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis., 2014, vol. 58, no. 3, pp. 381-391. https://doi.org/10.1093/cid/cit643Takizawa T., Hashimoto K., Minami T., Yamashita S., & Owen, K. (1999). The comparative arthropathy of fluoroquinolones in dogs // Human & Experimental Toxicology. – 1999. – Vol. 18, № 6. – Р. 392-399. https://doi.org/10.1191/096032799678840237Takizawa T., Hashimoto K., Minami T., Yamashita S., Owen, K. (1999). The comparative arthropathy of fluoroquinolones in dogs. Human and Experimental Toxicology, 1999, vol. 18, no. 6, pp. 392-399. https://doi.org/10.1191/096032799678840237Trieu L., Proops D.C., Ahuja S.D. Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA // Emerg Infect Dis. – 2015. – Vol. 21, № 3. – Р. 500-503. https://doi.org/10.3201/eid2103.141313Trieu L., Proops D.C., Ahuja S.D. Moxifloxacin prophylaxis against MDR TB, New York, New York, USA. Emerg. Infect. Dis., 2015, vol. 21, no. 3, pp. 500-503. https://doi.org/10.3201/eid2103.141313U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf [Accessed 27.09.2024]U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 as of July 2017. Available: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf Accessed September 27, 2024WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO, 2020.WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva, World Health Organization, Licence. CC BY-NC-SA 3.0 IGO, 2020.WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO, 2024.WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva, World Health Organization. Licence: CC BY-NC-SA 3 IGO. WHO, 2024.WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO, 2022.WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva, World Health Organization. Licence: CC BY-NC-SA 3.0 IGO, 2022.

The authors declare that there are no conflicts of interest present.